$88.61 -0.26 (-0.29%)

VanEck Pharmaceutical ETF (PPH)

Dividend Yield 2.2%
Payout Frequency Quarterly

Dividend History

Pay Date Amount Ex-Date Record Date
July 7, 2025 $0.61 2025-07-01 2025-07-01
April 4, 2025 $0.52 2025-04-01 2025-04-01
December 30, 2024 $0.41 2024-12-27 2024-12-27
October 4, 2024 $0.41 2024-10-01 2024-10-01
July 5, 2024 $0.36 2024-07-01 2024-07-01

Dividends Summary

Company News

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Zacks Investment Research • Zacks Equity Research • June 28, 2024

Smart Beta ETF report for PJP

Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage
Benzinga • Piero Cingari • March 8, 2024

Novo Nordisk A/S (NYSE:NVO)’s Wegovy garnered the Food and Drug Administration’s approval for expanded use Friday, marking what the drugmaker said is a pivotal turn in the treatment landscape for individuals grappling with the dual challenges of obesity and established cardiovascular disease. This approval underscores a new era in preventive health strategies, targeting a significant reduction in major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attacks (myocardial infarction) and nonfatal strokes. Leap Forward In Cardiovascular, Weight Management Therapy The FDA’s green light is anchored in the ...Full story available on Benzinga.com

NVO
Technology Leader Pushpay Announces Executive Leadership Hire, Welcomes Burt Y. Chao as Chief Financial Officer
GlobeNewswire Inc. • Pushpay • September 14, 2023

Chao will lead Pushpay’s finance and accounting teams, optimizing financial performance for the now privately held SaaS company Chao will lead Pushpay’s finance and accounting teams, optimizing financial performance for the now privately held SaaS company

Schumer provides 'rock-solid evidence' that Democrats will push forward with partisan tax and spending bill, analyst says
MarketWatch • MarketWatch • July 6, 2022

Democrats have long hoped to coalesce around a plan to roll back some of Donald Trump's tax cuts for wealthy individuals and corporations to pay for new spending on healthcare and the fight against climate change, and it appears that plan is finally taking shape.

AbbVie: Buy, Hold, Or Sell After Q1 Results?
Seeking Alpha • High Yield Investor • May 8, 2022

AbbVie stock was under heavy selling pressure following its Q1 ‘22 earnings. Check out whether ABBV stock is a buy, hold or sell after its Q1 earnings.